<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752085</url>
  </required_header>
  <id_info>
    <org_study_id>03-21</org_study_id>
    <nct_id>NCT04752085</nct_id>
  </id_info>
  <brief_title>Prognosis and Course of COVID-19 Infection in Hospitalised Patients</brief_title>
  <official_title>Prognosis and Course of COVID-19 Infection in Hospitalised Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the cohort prospective observational study is to define the major factors&#xD;
      influencing the course of COVID-19 infections and its prognosis in hospitalised patients.&#xD;
&#xD;
      The investigators plan to include 300 patients hospitalised with COVID-19 infection.&#xD;
&#xD;
      The phone contacts with patients are due after 90 and 180 days after discharge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Need in biological therapy or/and respiratory support</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>The primary endpoint is the need in biological therapy or/and respiratory support including NIV during hospital stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days spent in hospital</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>The investigators plan to assess the overall length of hospitalisation due to COVID-19 infection as an outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>90 days</time_frame>
    <description>To assess the all-cause death 90 days after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>180 days</time_frame>
    <description>To assess the all-cause death 180 days after discharge</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Chitotriosidase activity</intervention_name>
    <description>The chitotriosidase activity will be measured in all the subjects</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        300 patients hospitalised with COVID-19 infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalisation with COVID-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hospitalisation with COVID-19 infection&#xD;
&#xD;
          -  Discharge from the hospital before the end of the treatment course&#xD;
&#xD;
          -  Transfer to another hospital&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Mironova, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sechenov University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga Mironova, PhD</last_name>
    <phone>+79161735699</phone>
    <email>mironova_o_yu@staff.sechenov.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Panferov, PhD</last_name>
    <phone>+79166126865</phone>
    <email>a_panferov@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital #1</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Panfyorov, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital #4</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Balakhonov, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.M. Sechenov First Moscow State Medical University</investigator_affiliation>
    <investigator_full_name>Olga Mironova</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>chitotriosidase</keyword>
  <keyword>SARS-CoV Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

